These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 32851411)

  • 1. Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults.
    Sadoff J; De Paepe E; Haazen W; Omoruyi E; Bastian AR; Comeaux C; Heijnen E; Strout C; Schuitemaker H; Callendret B
    J Infect Dis; 2021 Feb; 223(4):699-708. PubMed ID: 32851411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years.
    Williams K; Bastian AR; Feldman RA; Omoruyi E; de Paepe E; Hendriks J; van Zeeburg H; Godeaux O; Langedijk JPM; Schuitemaker H; Sadoff J; Callendret B
    J Infect Dis; 2020 Aug; 222(6):979-988. PubMed ID: 32320465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults.
    Falsey AR; Williams K; Gymnopoulou E; Bart S; Ervin J; Bastian AR; Menten J; De Paepe E; Vandenberghe S; Chan EKH; Sadoff J; Douoguih M; Callendret B; Comeaux CA; Heijnen E;
    N Engl J Med; 2023 Feb; 388(7):609-620. PubMed ID: 36791161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months.
    Stuart ASV; Virta M; Williams K; Seppa I; Hartvickson R; Greenland M; Omoruyi E; Bastian AR; Haazen W; Salisch N; Gymnopoulou E; Callendret B; Faust SN; Snape MD; Heijnen E
    J Infect Dis; 2022 Dec; 227(1):71-82. PubMed ID: 36259542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials.
    Beran J; Lickliter JD; Schwarz TF; Johnson C; Chu L; Domachowske JB; Van Damme P; Withanage K; Fissette LA; David MP; Maleux K; Schmidt AC; Picciolato M; Dieussaert I
    J Infect Dis; 2018 Apr; 217(10):1616-1625. PubMed ID: 29401325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial.
    Schwarz TF; McPhee RA; Launay O; Leroux-Roels G; Talli J; Picciolato M; Gao F; Cai R; Nguyen TL; Dieussaert I; Miller JM; Schmidt AC
    J Infect Dis; 2019 Oct; 220(11):1816-1825. PubMed ID: 31418022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study.
    Sadoff J; De Paepe E; DeVincenzo J; Gymnopoulou E; Menten J; Murray B; Rosemary Bastian A; Vandebosch A; Haazen W; Noulin N; Comeaux C; Heijnen E; Eze K; Gilbert A; Lambkin-Williams R; Schuitemaker H; Callendret B
    J Infect Dis; 2022 Aug; 226(3):396-406. PubMed ID: 33400792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical models.
    Saeland E; van der Fits L; Bolder R; Heemskerk-van der Meer M; Drijver J; van Polanen Y; Vaneman C; Tettero L; Serroyen J; Schuitemaker H; Callendret B; Langedijk JPM; Zahn RC
    Vaccine; 2022 Feb; 40(6):934-944. PubMed ID: 34973849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine.
    Falsey AR; Walsh EE; Scott DA; Gurtman A; Zareba A; Jansen KU; Gruber WC; Dormitzer PR; Swanson KA; Jiang Q; Gomme E; Cooper D; Schmoele-Thoma B
    J Infect Dis; 2022 Jun; 225(12):2056-2066. PubMed ID: 34931667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant.
    Langley JM; Aggarwal N; Toma A; Halperin SA; McNeil SA; Fissette L; Dewé W; Leyssen M; Toussaint JF; Dieussaert I
    J Infect Dis; 2017 Jan; 215(1):24-33. PubMed ID: 27694633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
    Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
    Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses.
    Falloon J; Talbot HK; Curtis C; Ervin J; Krieger D; Dubovsky F; Takas T; Yu J; Yu L; Lambert SL; Villafana T; Esser MT
    Clin Vaccine Immunol; 2017 Sep; 24(9):. PubMed ID: 28679495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.
    Kieninger D; Sheldon E; Lin WY; Yu CJ; Bayas JM; Gabor JJ; Esen M; Fernandez Roure JL; Narejos Perez S; Alvarez Sanchez C; Feng Y; Claeys C; Peeters M; Innis BL; Jain V
    BMC Infect Dis; 2013 Jul; 13():343. PubMed ID: 23883186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults.
    Aliprantis AO; Shaw CA; Griffin P; Farinola N; Railkar RA; Cao X; Liu W; Sachs JR; Swenson CJ; Lee H; Cox KS; Spellman DS; Winstead CJ; Smolenov I; Lai E; Zaks T; Espeseth AS; Panther L
    Hum Vaccin Immunother; 2021 May; 17(5):1248-1261. PubMed ID: 33121346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
    Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
    Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
    Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model.
    Kim E; Okada K; Beeler JA; Crim RL; Piedra PA; Gilbert BE; Gambotto A
    J Virol; 2014 May; 88(9):5100-8. PubMed ID: 24574396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
    van de Witte S; Nauta J; Montomoli E; Weckx J
    Vaccine; 2018 Sep; 36(40):6030-6038. PubMed ID: 29709447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease.
    Lee YN; Hwang HS; Kim MC; Lee YT; Lee JS; Moore ML; Kang SM
    Antiviral Res; 2015 Mar; 115():1-8. PubMed ID: 25513755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.